Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

Date
2011
Author
Smith, Ian
Mauriac, Louis
Lang, Istvan
Forbes, John F.
Thuerlimann, Beat
Regan, Meredith M.
Neven, Patrick
Giobbie-Hurder, Anita
Goldhirsch, Aron
Ejlertsen, Bent
Coates, Alan S.
Gelber, Richard D.
Price, Karen N.
Rabaglio, Manuela
Wardley, Andrew
Metadata
Show full item record
Abstract
Background Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8.1 years median follow-up.
URI
http://hdl.handle.net/20.500.12627/178755
https://doi.org/10.1016/s1470-2045(11)70270-4
Collections